Your browser doesn't support javascript.
loading
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis.
Pala, Laura; De Pas, Tommaso; Stucchi, Erika; Catania, Chiara; Cocorocchio, Emilia; Zampino, Maria Giulia; Rossi, Giovanna; Zattarin, Emma; Di Muzio, Antonio; Laszlo, Daniele; Stucchi, Sara; Conforti, Fabio.
Afiliação
  • Pala L; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy. Electronic address: laura.pala@gavazzeni.it.
  • De Pas T; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Stucchi E; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy; Humanitas University, Rozzano, Italy.
  • Catania C; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Cocorocchio E; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Zampino MG; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
  • Rossi G; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Zattarin E; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Di Muzio A; Humanitas University, Rozzano, Italy.
  • Laszlo D; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Stucchi S; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Conforti F; Medical Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
Semin Oncol ; 50(6): 140-143, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38065801
ABSTRACT

INTRODUCTION:

Squamous cell carcinoma of the anus (SCCA) is a rare tumor. While most patients with locally advanced disease are cured with chemo-radiotherapy, about a quarter eventually experience metastatic recurrence. Standard treatment for advanced disease is chemotherapy, but recently evidence on the activity of immunotherapy has been reported. We performed a systematic review and meta-analysis of prospective trials testing immune-checkpoint inhibitors (ICIs) in patients with SCCA.

OBJECTIVE:

We aimed to evaluate the overall response rate (ORR) and the disease control rate (DCR) of ICIs in patients with advanced SCCA.

METHODS:

We systematically searched PubMed, Embase, and Scopus, through December 31, 2022, for prospective trials assessing ICIs in patients with advanced SCCA. The primary and secondary endpoints were respectively ORR and DCR.

RESULTS:

Six prospective trials were included in the analysis, one of which was randomized. Overall, seven treatment arms and 347 patients have been analyzed. Five treatment arms tested ICIs as monotherapy and two arms examined ICIs in combination with cetuximab and bevacizumab, respectively. The pooled ORR was 13% (95%CI, 10%-17%), with a DCR of 57% (95%CI, 40%-74%). Results did not change in a sensitivity analysis, which excluded the two treatment arms testing the combination of ICIs with other drugs.

CONCLUSIONS:

The efficacy of ICIs in SCCAs is low. Combination strategies with targeted drugs or chemotherapy might represent a better therapeutic strategy for these patients. Further studies are awaited to identify resistance mechanisms to ICIs and optimize their efficacy.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Inibidores de Checkpoint Imunológico Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Semin Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Inibidores de Checkpoint Imunológico Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: Semin Oncol Ano de publicação: 2023 Tipo de documento: Article